Market Overview:
The global oligonucleotide-based therapies market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for novel therapeutics, and technological advancements in the field of oligonucleotide-based therapies. The global oligonucleotide-based therapies market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into antisense oligonucleotides, aptamers, and other types. On the basis of application, the market is segmented into neuromuscular diseases (e.g., amyotrophic lateral sclerosis [ALS], spinal muscular atrophy [SMA]), hepatic VOD (venoocclusive disease), and other applications.
Product Definition:
Oligonucleotide-based therapies are treatments that use oligonucleotides to target and modify gene expression. Oligonucleotides are short, synthetic pieces of DNA or RNA that can be used to regulate gene expression by blocking the translation of specific genes, or by promoting the transcription of other genes. Oligonucleotide-based therapies are important because they can be used to treat a variety of diseases, including cancer and genetic disorders.
Antisense Oligonucleotide:
Antisense oligonucleotide is an artificial nucleic acid molecule that can be used for the modification of gene expression. It works by binding to the mRNA and preventing it from being translated into protein. The use of antisense technology in therapeutics has been growing rapidly over the past few years owing to its ability to reduce side effects caused by drugs, improve drug efficacy, increase patient compliance, and enhance treatment outcomes.
Aptamer:
Aptamers are short, linear molecules composed of four to six amino acids. They are non-covalent and highly specific binding proteins. Aptamers can bind with high specificity and efficacy to a wide range of target molecules including drugs, pathogens, cells, tissues & organs. Owing to their several biological activities such as anti-cancer activity they have been extensively studied over the past few years in various research projects across the globe.
Application Insights:
The global market is segmented by application into neuromuscular diseases, hepatic VOD, other and others. In 2017, the neuromusucle disease segment dominated the overall industry with a share of over 40% in terms of revenue. This high share was primarily due to factors such as an increase in prevalence rates of genetic disorders coupled with growing awareness about available treatment options for these disorders. For instance, according to data published by the CDC in 2018 regarding congenital heart defects; there were around 1 million babies diagnosed with CHD annually across the globe which comprises about 15% of all birth defects and occurs more frequently among black race compared to white infants.
In addition, oligonucleotide drugs have been proven effective against hepatic VOD since they can correct mutations that cause liver damage without causing harm to other organs or systems including kidney and bone marrow function.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, increased R&D expenditure by government and private entities, and high adoption rate for novel therapeutics in this region. The U.S.-based companies are engaged in extensive research activities to identify potential targets for new drugs as well as develop innovative drug delivery systems targeting chronic diseases such as cancer, diabetes & obesity, and other infectious diseases.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as increasing healthcare spending by governments along with that by private organizations; rising awareness about advanced treatments; growing base of aging population suffering from chronic disorders; availability of skilled labor at low cost; etc.). In addition, an increase in disposable income levels will boost demand for these therapies further driving regional market growth during the forecast period. Moreover Oligonucleotide Therapeutics (OXT) Ltd.
Growth Factors:
- Increasing demand for personalized medicines
- Rising prevalence of chronic diseases
- Growing investments in R&D by pharmaceutical companies
- Technological advancements in oligonucleotide-based therapies
- Increasing awareness about the benefits of oligonucleotide-based therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Oligonucleotide-based Therapies Market Research Report
By Type
Antisense Oligonucleotide, Aptamer, Other
By Application
Neuromuscular Diseases, Hepatic VOD, Other
By Companies
Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
143
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Oligonucleotide-based Therapies Market Report Segments:
The global Oligonucleotide-based Therapies market is segmented on the basis of:
Types
Antisense Oligonucleotide, Aptamer, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Neuromuscular Diseases, Hepatic VOD, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen
- Sarepta Therapeutics
- Jazz Pharmaceuticals
- Bausch & Lomb
- Alnylam Pharmaceuticals
- Dynavax Technologies
- Kastle therapeutics
- Akcea Therapeutics
Highlights of The Oligonucleotide-based Therapies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antisense Oligonucleotide
- Aptamer
- Other
- By Application:
- Neuromuscular Diseases
- Hepatic VOD
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oligonucleotide-based Therapies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oligonucleotide-based therapies are treatments that use oligonucleotides as the therapeutic agent. Oligonucleotides are short pieces of DNA or RNA. They can be used to treat a variety of diseases and conditions, including cancer, Alzheimer's disease, and HIV/AIDS.
Some of the major companies in the oligonucleotide-based therapies market are Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics.
The oligonucleotide-based therapies market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oligonucleotide-based Therapies Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oligonucleotide-based Therapies Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oligonucleotide-based Therapies Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oligonucleotide-based Therapies Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oligonucleotide-based Therapies Market Size & Forecast, 2018-2028
4.5.1 Oligonucleotide-based Therapies Market Size and Y-o-Y Growth
4.5.2 Oligonucleotide-based Therapies Market Absolute $ Opportunity
Chapter 5 Global Oligonucleotide-based Therapies Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Oligonucleotide-based Therapies Market Size Forecast by Type
5.2.1 Antisense Oligonucleotide
5.2.2 Aptamer
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Oligonucleotide-based Therapies Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Oligonucleotide-based Therapies Market Size Forecast by Applications
6.2.1 Neuromuscular Diseases
6.2.2 Hepatic VOD
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oligonucleotide-based Therapies Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oligonucleotide-based Therapies Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Oligonucleotide-based Therapies Analysis and Forecast
9.1 Introduction
9.2 North America Oligonucleotide-based Therapies Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Oligonucleotide-based Therapies Market Size Forecast by Type
9.6.1 Antisense Oligonucleotide
9.6.2 Aptamer
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Oligonucleotide-based Therapies Market Size Forecast by Applications
9.10.1 Neuromuscular Diseases
9.10.2 Hepatic VOD
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Oligonucleotide-based Therapies Analysis and Forecast
10.1 Introduction
10.2 Europe Oligonucleotide-based Therapies Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Oligonucleotide-based Therapies Market Size Forecast by Type
10.6.1 Antisense Oligonucleotide
10.6.2 Aptamer
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Oligonucleotide-based Therapies Market Size Forecast by Applications
10.10.1 Neuromuscular Diseases
10.10.2 Hepatic VOD
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Oligonucleotide-based Therapies Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Oligonucleotide-based Therapies Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Oligonucleotide-based Therapies Market Size Forecast by Type
11.6.1 Antisense Oligonucleotide
11.6.2 Aptamer
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Oligonucleotide-based Therapies Market Size Forecast by Applications
11.10.1 Neuromuscular Diseases
11.10.2 Hepatic VOD
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Oligonucleotide-based Therapies Analysis and Forecast
12.1 Introduction
12.2 Latin America Oligonucleotide-based Therapies Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Oligonucleotide-based Therapies Market Size Forecast by Type
12.6.1 Antisense Oligonucleotide
12.6.2 Aptamer
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Oligonucleotide-based Therapies Market Size Forecast by Applications
12.10.1 Neuromuscular Diseases
12.10.2 Hepatic VOD
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Oligonucleotide-based Therapies Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Oligonucleotide-based Therapies Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Oligonucleotide-based Therapies Market Size Forecast by Type
13.6.1 Antisense Oligonucleotide
13.6.2 Aptamer
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Oligonucleotide-based Therapies Market Size Forecast by Applications
13.10.1 Neuromuscular Diseases
13.10.2 Hepatic VOD
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oligonucleotide-based Therapies Market: Competitive Dashboard
14.2 Global Oligonucleotide-based Therapies Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biogen
14.3.2 Sarepta Therapeutics
14.3.3 Jazz Pharmaceuticals
14.3.4 Bausch & Lomb
14.3.5 Alnylam Pharmaceuticals
14.3.6 Dynavax Technologies
14.3.7 Kastle therapeutics
14.3.8 Akcea Therapeutics
